Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis
Authors:
- 4 November 2025
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 89 (1) , 31-44
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN studyEuropean Journal of Cancer, 2023
- Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung CancerJAMA Oncology, 2023
- The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESEuropean Urology, 2023
- First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate CancerJAMA Oncology, 2023
- Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022European Journal of Cancer, 2023
- Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate CancerEuropean Urology, 2019
- Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate CancerEuropean Urology, 2019
- Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)The Prostate, 2018
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 TrialEuropean Urology, 2016
- Consistency and inconsistency in network meta‐analysis: model estimation using multivariate meta‐regressionResearch Synthesis Methods, 2012